Caribou Biosciences

Yahoo Finance • 2 months ago

Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street

Caribou Biosciences, Inc. (NASDAQ:CRBU) is included in our list of the 7 most volatile stocks under $5 for day trading.Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street A dose bottle... Full story

Yahoo Finance • 2 months ago

Genomics Stocks That Deserve a Place in Your Portfolio in 2026

An updated edition of the Jan. 6, 2026, article. Genomics is the comprehensive study of genomes—the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pha... Full story

Yahoo Finance • 3 months ago

February 2026's Promising Penny Stocks To Consider

As February 2026 begins, the U.S. stock market has seen a robust start, with major indexes like the Dow Jones Industrial Average and S&P 500 posting significant gains. This positive momentum reflects broader economic optimism and renewed i... Full story

Yahoo Finance • 4 months ago

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physi... Full story

Yahoo Finance • 5 months ago

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE... Full story

Yahoo Finance • 6 months ago

Caribou Bioscience GAAP EPS of -$0.30 beats by $0.07, revenue of $2.2M misses by $0.07M

* Caribou Bioscience press release [https://seekingalpha.com/pr/20305067-caribou-biosciences-reports-third-quarter-2025-financial-results-and-provides-business-update] (CRBU [https://seekingalpha.com/symbol/CRBU]): Q3 GAAP EPS of -$0.30... Full story

Yahoo Finance • 6 months ago

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma 450 million cell dose is the recommended dose for expansion (RDE); dose expansi... Full story

Yahoo Finance • 6 months ago

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at 8:00 am ET o... Full story

Yahoo Finance • 8 months ago

August 2025's Top Penny Stocks With Growth Potential

As the U.S. stock market inches higher, with major indices nearing record highs, investors are closely watching key developments such as Nvidia's earnings report and shifts in Federal Reserve policy. Amid these broader market dynamics, pen... Full story

Yahoo Finance • 8 months ago

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief e... Full story

Yahoo Finance • 9 months ago

Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss

CARIBOU BIOSCIENCES INC (NASDAQ:CRBU [https://www.chartmill.com/stock/quote/CRBU]) REPORTS Q2 2025 EARNINGS: MIXED RESULTS AND MARKET REACTION Caribou Biosciences Inc (NASDAQ:CRBU [https://www.chartmill.com/stock/quote/CRBU]) released its... Full story

Yahoo Finance • 9 months ago

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Caribou (CRBU) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Caribou between July 14, 2023... Full story

Yahoo Finance • 11 months ago

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief ex... Full story

Yahoo Finance • last year

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4 million in cash, cash equivalents,... Full story

Yahoo Finance • last year

Caribou Biosciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; February 24, 2025 Deadline to file Lead Plaintiff Motion

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 24, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Caribou Biosciences, Inc. ("Caribou " or the "Company") (NASDAQ: CRBU)... Full story

Yahoo Finance • last year

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Caribou Biosciences, Inc. (CRBU) Shareholders

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. CLASS DEFINITION: The... Full story

Yahoo Finance • last year

CRBU DEADLINE NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 24 Deadline in Securities Class Action – CRBU

NEW YORK, Feb. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 16, 2024, both dates inclusi... Full story

Yahoo Finance • last year

Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. CLASS DEFINITION: The... Full story

Yahoo Finance • last year

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU during the class period listed are encoura... Full story

Yahoo Finance • last year

CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“C... Full story